Clinical Trial Update: Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the safety and tolerability of initiating LCZ696 (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan) (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2015-10-15